Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 1) 2024
© 2026 Zoe. All rights reserved.
Zoe is a legal information platform. Always consult the Federal Register of Legislation for authoritative text.
Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 1) 2024
Start here
Turn the raw legal text into a practical explanation grounded in Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 1) 2024.
(1) A medical device must not be listed in Part C of Schedule 1 unless subsections (2) and (3) are satisfied. (2) The medical device must be one of the following: (a) an insulin infusion pump; (b) an electronic device and software designed to control an insulin infusion pump; (c) an implantable cardiac event recorder; (d) a cardiac home/remote monitoring system; (e) an irrigated cardiac ablation catheter; (f) a mapping catheter for catheter cardiac ablation; (g) a patch for cardiac ablation; (h) a monopolar device for surgical cardiac ablation; (i) a bipolar device for surgical cardiac ablation; (j) a system for surgical cardiac ablation; (k) a probe for surgical cardiac ablation; (l) a non‑irrigated cardiac ablation catheter; (m) an intracardiac electrophysiology catheter; (n) a vascular drug eluting balloon catheter; (o) a coronary drug eluting balloon catheter; (p) a radiofrequency delivery device for transurethral water vapour ablation (TUWA).
Note: This instrument may be varied from time to time to add additional devices to, or remove devices from, subsection 16(2).
(3) Both of the following must be satisfied: (a) the medical device must have been compared to: (i) alternative devices listed in Schedule 1; or (ii) alternative treatments; (b) the comparison must demonstrate that: (i) the medical device is no less clinically effective than the alternative devices or the alternative treatments; and (ii) the benefit amount for the medical device is proportionate to the clinical‑effectiveness of the medical device.